Antibacterial peptide as well as preparation method and application thereof

By designing and synthesizing L-configured LR-11 and D-configured DR-11 antibacterial peptides, the problem of antibiotic-resistant bacteria is solved, and effective inhibition of various bacteria and prevention and treatment of silkworm bacterial diseases is achieved. , has good thermal stability and low cytotoxicity.

CN118930610APending Publication Date: 2024-11-12CHONGQING UNIV OF TECH +1
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411171220.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing antibiotics are increasing resistance to some bacteria, resulting in the ineffectiveness of traditional treatment methods. New antibiotics are needed to deal with pathogens such as Enterococcus, Streptococcus pneumoniae, Enterobacteria, Staphylococcus aureus.

Method used

A new antimicrobial peptide was designed with the sequences of L-configuration LR-11 and D-configuration DR-11. It was synthesized by Fmoc solid-phase chemistry method, with good thermal stability, salt stability and low Cytotoxicity and optimized design for the active site of the bacterial outer membrane protein BamA.

Benefits of technology

It has achieved the effectiveness of a variety of antibacterial infections, including Staphylococcus aureus, Pseudomonas aeruginosa, etc., and has performed well in the prevention and treatment of home silkworm bacterial diseases, reducing the mortality rate of Enterococcus Montessori and has important application value. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930610A_ABST
    Figure CN118930610A_ABST
Patent Text Reader

Abstract

The invention discloses an antibacterial peptide and a preparation method and application thereof, and the antibacterial peptide is characterized in that the antibacterial peptide is an L-configuration amino acid sequence LR-11: R (L)-K (L)-W (L)-F (L)-R (L)-R (L)-W (L)-R (L)-W (L)-V (L) (Arg-Lys-Try-Phe-Arg-Arg-Trp-Arg-Arg-Try-Val); or the amino acid sequence is a D-configuration amino acid sequence DR-11: R (D)-K (D)-W (D)-F (D)-R (D)-R (D)-W (D)-V (D) (Arg-Lys-Try-Phe-Arg-Arg-Trp-Arg-Arg-Try-Val). The two antibacterial peptides designed by the invention have good thermal stability, salt stability and protease tolerance, have good antibacterial activity, low cytotoxicity and hemolytic toxicity, and have great development potential and application value. In addition, the antibacterial peptide has excellent performance in prevention and treatment of silkworm diseases, can effectively reduce the fatality rate of silkworm pathogenic bacteria enterococcus monteilii, and has important application value in sericulture.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of polypeptides, and in particular to an antimicrobial peptide and a preparation method and application thereof. Background Art

[0002] Bacterial infection is a common but serious health hazard. Its research status has always attracted much attention. With the continuous increase of antibiotic-resistant bacteria, finding new antibiotics has become one of the important challenges in today's medical field. The World Health Organization has released a priority list of antibiotic-resistant bacteria and tuberculosis. The list lists a series of bacteria that pose a serious threat to human health, including enterococci, Streptococcus pneumoniae, Enterobacter, Staphylococcus aureus, etc. These bacteria have shown strong resistance to currently commonly used antibiotics, making traditional treatments ineffective, so finding new antibiotics has become a top priority.

[0003] Antimicrobial peptides (AMPs) are a class of polypeptide molecules with antimicrobial activity, which were originally discovered from natural sources such as humans, animals, plants and microorganisms. Antimicrobial peptides are considered to be a potential new type of antimicrobial drug. Its mechanism of action mainly includes destroying bacterial cell membranes, interfering with bacterial protein synthesis, inhibiting bacterial DNA and RNA synthesis, etc. to kill a variety of pathogens and effectively fight various bacteria, fungi, viruses and other pathogenic microorganisms. With the development of biotechnology, people gradually understand the structure and function of antimicrobial peptides, and begin to design new antimicrobial peptides through synthesis and modification.

[0004] After being synthesized in the cytoplasm, outer membrane proteins are transported to the periplasm through the inner membrane. After being cleaved by signal peptidase, unfolded outer membrane proteins are formed. They are transported to the β-barrel protein assembly machinery (Bam) by molecular chaperones, and then correctly folded into "β-barrel" by Bam and inserted into the outer membrane. Accumulation of unfolded outer membrane proteins in the periplasm will cause toxicity. BamA occupies a core position in the β-barrel assembly machinery (BAM) complex. As a basic component of outer membrane proteins, it shoulders a vital mission. First, as a key element of the outer membrane protein insertion pathway, it interacts with outer membrane proteins to promote their insertion into the outer membrane of the cell; secondly, it plays the role of a signal transduction molecule in the life process of bacteria, and has an indispensable influence on the growth, reproduction and regulation of bacterial pathogenicity. BamA is a potential ideal target for the development of new antibiotics. Summary of the invention

[0005] In view of the above technical problems, the purpose of the present invention is to provide a new antimicrobial peptide, and the present invention also provides a preparation method and application of the antimicrobial peptide, which has good thermal stability, salt stability and low cytotoxicity.

[0006] In order to achieve the above first object, the present invention provides an antimicrobial peptide, characterized in that it is an L-configuration amino acid.

[0007] Amino acid sequence LR-11:

[0008] R(L)-K(L)-W(L)-F(L)-R(L)-R(L)-W(L)-R(L)-R(L)-W(L)-V(L)(Arg-Lys-Try-Phe-Ar g-Arg-Trp-Arg-Arg-Try-Val);

[0009] Or it is the D-configuration amino acid sequence DR-11: R(D)-K(D)-W(D)-F(D)-R(D)-R(D)-W(D)-V(D) (Arg-Lys-Try-Phe-Arg-Arg-Trp-Arg-Arg-Try-Val).

[0010] The second object of the present invention is achieved by using the antimicrobial peptide in the preparation of antimicrobial infection drugs.

[0011] In the above scheme: the antimicrobial peptide is used in the preparation of drugs against Staphylococcus aureus (ATCC29213), Pseudomonas aeruginosa (ATCC27853), Enterococcus faecalis (ATCC19434), carbapenem-resistant Pseudomonas aeruginosa (CRPA), multidrug-resistant Acinetobacter baumannii (MDRAB), Escherichia coli (ATCC25922), Klebsiella pneumoniae (ATCC700603), and Acinetobacter baumannii (ATCC19606).

[0012] The antimicrobial peptide is used in preparing drugs for preventing and treating silkworm bacterial diseases.

[0013] In the above scheme: the antimicrobial peptide is used in the preparation of in vivo and in vitro drugs against Enterococcus monnieri, a pathogenic bacterium of silkworm.

[0014] A method for preparing the antimicrobial peptide is characterized in that: the polypeptide is synthesized by solid phase synthesis, MBHA resin is selected as a solid phase carrier, the resin is first swelled and then the protecting group is removed, the first amino acid is connected to the resin, and then the remaining amino acids are connected to the resin in sequence, and the Fmoc protecting group on the amino acid is removed after each connection, and after the connection of all peptide chains is completed, the antimicrobial peptide is cut from the resin and separated and purified by high performance liquid chromatography.

[0015] In the above scheme: when connecting amino acids, an activator O-benzotriazole-tetramethyluronium hexafluorophosphate is used to promote the coupling reaction of the amino group and the carboxyl group.

[0016] In the above scheme: the Fmoc protecting group on the amino acid is removed using an N,N-dimethylformamide solution containing 20% ​​piperidine by volume.

[0017] In the above scheme: a mixed solution of trifluoroacetic acid, water and triisopropylsilane in a volume ratio of 95%:2.5%:2.5% is used as a cutting liquid to cut the antimicrobial peptide from the resin.

[0018] The inventors of the present invention targeted the active site of the bacterial outer membrane protein BamA, analyzed the conservative amino acid sequence and structure-activity relationship, key sites and dominant amino acids (RW) of the antimicrobial peptide sequence, and used D-amino acids to replace L-amino acids in order to solve the proteolytic instability of the antimicrobial peptide. Finally, L-configuration LR-11 and D-configuration DR-11 were optimized and designed.

[0019] The two antimicrobial peptides designed by the present invention have good thermal stability, salt stability, protease tolerance, good antimicrobial activity, low cytotoxicity and hemolytic toxicity, and have great development potential and application value. In addition, the antimicrobial peptides also perform well in the prevention and treatment of silkworm diseases, can effectively reduce the mortality rate of silkworm pathogenic bacteria Enterococcus monnieri, and have important application value in silkworm breeding.

[0020] The antimicrobial peptide provided by the present invention is synthesized by Fmoc solid phase chemical method, has strong operability, low cost, good antimicrobial activity and low preparation difficulty. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Schematic diagram of the binding of antimicrobial peptide LR-11 to target protein BamA.

[0022] Figure 2 Schematic diagram of the binding of antimicrobial peptide DR-11 to target protein BamA.

[0023] Figure 3 The liquid chromatogram and mass spectrum of the antimicrobial peptide LR-11.

[0024] Figure 4 These are the liquid chromatogram and mass spectrum of the antimicrobial peptide DR-11.

[0025] Figure 5 The hemolytic toxicity of antimicrobial peptides LR-11 and DR-11.

[0026] Figure 6 Cell viability of antimicrobial peptides LR-11 and DR-11.

[0027] Figure 7 The antimicrobial peptides LR-11 and DR-11 are effective against bacterial diseases of silkworms in vitro and in vivo. DETAILED DESCRIPTION

[0028] The present invention will be further described below by way of embodiments and in conjunction with the accompanying drawings:

[0029] Experimental Example 1

[0030] Design of antimicrobial peptides: The present invention analyzes the conservative amino acid sequences and structure-activity relationships of antimicrobial peptide sequences, determines the dominant amino acids (RW), targets the active binding sites of the bacterial outer membrane protein BamA, and ultimately optimizes the design of the L-configuration antimicrobial peptide LR-11 and the D-configuration antimicrobial peptide DR-11.

[0031] The LR-11 sequence is: R(L)-K(L)-W(L)-F(L)-R(L)-R(L)-W(L)-R(L)-W(L)-V(L)(Arg-Lys-Try-Phe-Arg-Arg-Trp-Arg-Arg-Try-Val).

[0032] The sequence of DR-11 is: R(D)-K(D)-W(D)-F(D)-R(D)-R(D)-W(D)-R(D)-W(D)-V(D)(Arg-Lys-Try-Phe-Arg-Arg-Trp-Arg-Arg-Try-Val).

[0033] Synthesis of antimicrobial peptides

[0034] The target product LR-11.DR-11 was synthesized according to the standard Fmoc solid phase procedure. The synthesized product was purified by high-purity silica gel chromatography (SHIMADZU Inertsil ODS-SP) using: Phase A: 0.1% trifluoroacetic acid-water solution

[0035] Phase B: 0.1% trifluoroacetic acid in acetonitrile

[0036] 1. Activation and pretreatment of resin

[0037] Accurately weigh 0.47 g of MBHA (4-toluenehydroamine) resin (0.43 mmol / g) and place it in a peptide solid phase synthesizer. After swelling with dichloromethane solution for 30 minutes, the resin was tested by ninhydrin colorimetry and it was colorless and transparent, indicating that the resin was normal.

[0038] 2. Preparation of antimicrobial peptides

[0039] The above-mentioned normal MBHA resin was subjected to a DMF solution containing 20% ​​piperidine by volume to remove the Fmoc protecting group. The resin was tested by the ninhydrin colorimetric method, and the resin was blue-purple, indicating that the protecting group had been removed. Then the first amino acid was connected to the resin, and the activator HBTU (O-benzotriazole-tetramethyluronium hexafluorophosphate) was used to promote the coupling reaction of the amino group and the carboxyl group; then the remaining amino acids were connected to the resin in sequence, and after each connection, the Fmoc protecting group on the amino acid was removed with an N,N-dimethylformamide solution containing 20% ​​piperidine by volume. According to the above method, the amino acids of the antimicrobial peptide were connected to the resin carrier in sequence. After the connection of all peptide chains was completed, the antimicrobial peptide was finally cut off from the resin using a mixed solution of trifluoroacetic acid, water, and triisopropylsilane in a volume ratio of 95%:2.5%:2.5% as a cutting liquid. The obtained reaction solution is filtered and the filtrate is collected, and then the polypeptide is precipitated after washing with ice ether. After centrifugation, the supernatant is discarded and the crude peptide is obtained by drying.

[0040] 3. Purification of antimicrobial peptides

[0041] The crude peptide was dissolved in acetonitrile and filtered using a 0.45 μM filter membrane. The filtrate was separated and purified using high performance liquid chromatography. Mobile phase A was 0.1% trifluoroacetic acid-water solution, mobile phase B was 0.1% trifluoroacetic acid-water solution, the flow rate was set to 1 ml / min, and the detection wavelength was 220 nm. Gradient elution was used to increase the proportion of mobile phase B from 2% to 6% within 20 minutes, and the target peptide sample was finally obtained.

[0042] Experimental Example 1

[0043] Antimicrobial activity test of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of antimicrobial peptides

[0044] Strains: Pseudomonas aeruginosa (ATCC27853), carbapenem-resistant Pseudomonas aeruginosa (CRPA), Klebsiella pneumoniae (ATCC700603), Acinetobacter baumannii (ATCC19606), Escherichia coli (ATCC25922), Staphylococcus aureus (ATCC29213), multidrug-resistant Acinetobacter baumannii (MDRAB), Enterococcus faecalis (ATCC19434).

[0045] The activity test method is as follows:

[0046] First, the frozen bacteria were taken out for resuscitation and activation, and then cultured in a constant temperature shaker until the logarithmic phase, and then the bacterial solution was diluted to 3×10 5CFU / mL. Use a pipette to add 100 μL of diluted bacterial solution to a sterile 96-well bacterial culture plate, then add 100 μL of the pre-prepared antimicrobial peptide solution with a concentration of 512 μg / mL to the first bacterial solution well in each column, and use the two-fold dilution method to dilute the drug concentration in sequence, then aspirate and discard the excess 100 μL of bacterial solution from the last bacterial solution well, so that the final drug concentrations are 256 μg / mL, 128 μg / mL, 64 μg / mL, 32 μg / mL, 16 μg / mL, 8 μg / mL, 4 μg / mL, and 2 μg / mL, respectively. After the operation, the 96-well bacterial culture plate was placed in a 37°C biochemical incubator for incubation for 12-14 hours. The turbidity in each group of bacterial solution wells was observed, and the OD600 value of each well of the bacterial solution was determined by a multifunctional microplate reader. The antimicrobial peptide concentration with no visible bacterial growth was the minimum inhibitory concentration (MIC). After determining the MIC of the antimicrobial peptide, 20 μL of the liquid in the wells without bacterial growth was respectively aspirated from the 96-well bacterial culture plate, spread on the LB solid culture medium without drugs, placed in a 37°C biochemical incubator for incubation for 12-14 hours, and then taken out to observe whether there was colony growth on the culture medium. The lowest concentration without bacterial growth was the minimum bactericidal concentration (MBC). The experiment was repeated three times.

[0047] Table 1 Antimicrobial activity of antimicrobial peptides LR-11 and DR-11

[0048]

[0049] The results are shown in Table 1. The antimicrobial peptides LR-11 and DR-11 have strong antibacterial activity against both Gram-positive and Gram-negative bacteria.

[0050] Experimental Example 2. Antimicrobial peptide stability test

[0051] 1) Salt stability

[0052] Diluted bacterial solution and gradient diluted antimicrobial peptides were added to a sterile 96-well bacterial culture plate, and then salt ion solutions of different concentrations (2.5 mM BaCl2, 4 mM FeCl3, 150 mM NaCl, 2.5 mM CaCl2) were added respectively. The MIC of the antimicrobial peptides against carbapenem-resistant Pseudomonas aeruginosa (CRPA) was determined according to the method described in Experimental Example 1 above, wherein the control group was untreated antimicrobial peptides, and the experiment was repeated 3 times.

[0053] Table 2 MIC values ​​of antimicrobial peptides LR-11 and DR-11 in different physiological salt solutions (μg / mL)

[0054]

[0055]

[0056] 2) Serum stability

[0057] The bacterial solution and the serially diluted antimicrobial peptide solution were added to a 96-well plate, and then different concentrations of sterile fetal bovine serum (mass concentrations were 0%, 5% and 10%) were added respectively. The MIC of the antimicrobial peptide against carbapenem-resistant Pseudomonas aeruginosa (CRPA) was determined according to the method described in Experimental Example 1, wherein the control group was untreated antimicrobial peptide, and the experiment was repeated 3 times.

[0058] Table 3 MIC values ​​of antimicrobial peptides LR-11 and DR-11 in different fetal bovine serum (μg / mL)

[0059]

[0060] 3) Protease resistance

[0061] First, add the diluted bacterial solution to the sterile 96-well bacterial culture plate, and then add trypsin, papain, and proteinase K respectively, so that the final concentration of each protease is 1 mg / mL. Then add the continuously diluted antimicrobial peptide solution and mix. First incubate at 37°C for 1 hour, then inactivate the protease in a 60°C water bath, and determine the MIC of the antimicrobial peptide against carbapenem-resistant Pseudomonas aeruginosa (CRPA) according to the method described in Experimental Example 1, where the control group is the untreated antimicrobial peptide, and the experiment is repeated 3 times.

[0062] Table 4 MIC values ​​of antimicrobial peptides LR-11 and DR-11 under different protease conditions (μg / mL)

[0063]

[0064] 4) Temperature tolerance

[0065] Diluted bacterial solution and serially diluted antimicrobial peptide solution were added to a sterile 96-well bacterial culture plate. Then, the plates were incubated at 0°C, 37°C, and 100°C for 1 h, and the MIC of the antimicrobial peptide against carbapenem-resistant Pseudomonas aeruginosa (CRPA) was determined according to the method described in Experimental Example 1, wherein the control group was untreated antimicrobial peptide, and the experiment was repeated 3 times.

[0066] Table 5 MIC values ​​of antimicrobial peptides LR-11 and DR-11 at different temperatures (μg / mL)

[0067]

[0068] 5) pH tolerance of antimicrobial peptides

[0069] First, add the diluted bacterial solution to a sterile 96-well bacterial culture plate, and then add a certain concentration of antimicrobial peptide solution to mix, (256μg / mL, 128μg / mL, 64μg / mL, 32μg / mL, 16μg / mL, 8μg / mL, 4μg / mL, 2μg / mL). Then use hydrochloric acid (HCl) and sodium hydroxide (NaOH) to prepare buffers of different pH (4, 6, 8, 10), so that the antimicrobial peptide is reacted in buffers of different pH (4, 6, 8, 10). The MIC of the antimicrobial peptide against carbapenem-resistant Pseudomonas aeruginosa (CRPA) was determined according to the method described in Experimental Example 1, in which the control group was an untreated antimicrobial peptide, and the experiment was repeated 3 times.

[0070] Table 6 MIC values ​​of antimicrobial peptides LR-11 and DR-11 at different pH values ​​(μg / mL)

[0071]

[0072] Experimental Example 3. Hemolytic toxicity of antimicrobial peptides

[0073] Take an appropriate amount of fresh sterile defatted sheep blood, centrifuge it at 4°C and low speed (3000rpm / min) for 10min, pour off the supernatant, wash and resuspend it with physiological saline, wash it 3 times and dilute it to 3% red blood cell suspension for use. First add 100μL of red blood cell suspension to the EP tube, and then add 100μL of different concentrations of antimicrobial peptide solution (256μg / mL, 128μg / mL, 64μg / mL, 32μg / mL, 16μg / mL, 8μg / mL, 4μg / mL, 2μg / mL) to mix them thoroughly. Add an equal volume of sterile PBS solution to the negative control, and add an equal volume of 0.1% Triton-X100 solution to the positive control. After the operation is completed, put it in a 37°C biochemical incubator and incubate it for 0.5h. The mixture was then centrifuged at a low speed (3000 rpm / min) for 10 min, and 100 μL of the supernatant was pipetted into a sterile 96-well bacterial culture plate to determine its OD570 value. The experiment was repeated 3 times and the average value was taken to calculate the hemolysis rate, which was calculated using the following equation:

[0074]

[0075] Figure 5 The results of the hemolytic toxicity experiment show that from the overall trend, both antimicrobial peptides are significantly different from the positive control group and are concentration-dependent. DR-11 has lower hemolytic toxicity than LR-11, indicating that the two designed antimicrobial peptides are very safe and have extremely high drugability.

[0076] Experimental Example 4

[0077] Antimicrobial peptide cytotoxicity assay

[0078] NCM460 was cultured in DMEM complete medium, and cells cultured to the third generation or later were used for the experiment. The cells were washed with PBS solution (phosphate buffer solution), digested with trypsin, and centrifuged. Then, DMEM complete medium was added, and the cell suspension density was 4×10 4 / mL. This suspension was added to a sterile 96-well cell culture plate, 90 μL was added to each well, and after culturing in a CO2 incubator for 12 hours, 10 μL of antimicrobial peptide solutions of different concentrations were added to each well, respectively, to make the final concentrations of 256 μg / mL, 128 μg / mL, 64 μg / mL, 32 μg / mL, 16 μg / mL, 8 μg / mL, 4 μg / mL, and 2 μg / mL, and then returned to the CO2 incubator and continued to be cultured at 37°C for 10 hours. After that, 10 μL of CCK-8 solution was added to each well, and then cultured for another 2 hours. The OD450 value was determined using a multifunctional microplate reader. The positive control group was a cell suspension with an equal volume of DMEM complete medium, and the blank group contained only DMEM complete medium. Three parallel groups were set up in each group. The formula for calculating the activity of antimicrobial peptides for NCM460 cells is as follows:

[0079]

[0080] Figure 6 As for the cytotoxicity results of antimicrobial peptides, the cytotoxicity of LR-11 and DR-11 is relatively low overall. In general, the two have relatively small effects on cell growth at the bactericidal dosage, and can be further developed and studied as antimicrobial candidate drugs.

[0081] Experimental Example 5. Application of antimicrobial peptides in treating bacterial diseases of silkworms

[0082] The in vitro antimicrobial peptide activity against Enterococcus monnieri pathogenic bacteria of silkworms was tested as described in Experimental Example 1. The in vivo antimicrobial activity of the antimicrobial peptide was tested as follows: Enterococcus monnieri was cultured in liquid LB medium until the logarithmic growth phase, 1 mL of the bacterial solution was taken out, centrifuged at 3000 rpm / min for 5 min, and then washed twice with PBS solution to prepare a concentration of 1×10 10CFU / mL bacterial suspension. Prepare fresh mulberry leaves and dry them, cut them into small pieces of 2cm×2cm, and then evenly apply 20μl of bacterial solution on the surface of the mulberry leaves and dry them. Feed the silkworms to the fifth instar stage, first fast for 12 hours to make them hungry, then feed each silkworm a piece of fresh mulberry leaf coated with bacterial solution, wait for the silkworms to finish eating, and transfer them to a new culture dish for grouping. The experimental group continued to feed fresh mulberry leaves evenly coated with 20μl of LR-11 and DR-11 solutions, and the control group was fed with fresh mulberry leaves coated with an equal amount of sterile water. After feeding antimicrobial peptides, the silkworms continued to be fed normally with fresh mulberry leaves at 25℃, and the survival and death of each group of silkworms were observed, and the number of deaths was recorded.

[0083] Table 7 MIC values ​​of antimicrobial peptides LR-11 and DR-11 against silkworm pathogens

[0084]

[0085] Figure 7 According to the results of this experiment, when the silkworms were fed with mulberry leaves treated with Enterococcus monteri, some of them stopped eating and had diarrhea, but the number of healthy silkworms in the experimental group was higher. During the feeding period, silkworms gradually died, and many of them were significantly smaller than normal silkworms when they died, and some of them had black back swelling. The experimental group fed with LR-11 and DR-11 solutions had a survival rate of 50% until the silkworms successfully formed cocoons, and the silkworms were in a healthy state, indicating that LR-11 and DR-11 have a certain preventive and therapeutic effect on bacterial diseases of silkworms, and can improve the survival rate of silkworms after infection, which has great application value for the prevention and treatment of bacterial diseases of silkworms.

[0086] The present invention is not limited to the above-mentioned embodiments. Those skilled in the art will appreciate that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and purpose of the present invention. The scope of the present invention is defined by the claims and their equivalents.

Claims

1. An antimicrobial peptide, characterized in that: The amino acid sequence of L-configuration LR-11 is: R(L)-K(L)-W(L)-F(L)-R(L)-R(L)-W(L)-R(L)-R(L)-W(L)-V(L)(Arg-Lys-Try-Phe-Arg-Arg-Trp-Arg-Arg-Try-Val); Or it is the D-configuration amino acid sequence DR-11: R(D)-K(D)-W(D)-F(D)-R(D)-R(D)-W(D)-V(D) (Arg-Lys-Try-Phe-Arg-Arg-Trp-Arg-Arg-Try-Val).

2. Use of the antimicrobial peptide according to claim 1 in the preparation of antimicrobial infection drugs.

3. The use of the antimicrobial peptide according to claim 2 in the preparation of antimicrobial infection drugs, characterized in that: The antimicrobial peptide is used in the preparation of drugs against Staphylococcus aureus (ATCC29213), Pseudomonas aeruginosa (ATCC27853), Enterococcus faecalis (ATCC19434), carbapenem-resistant Pseudomonas aeruginosa (CRPA), multidrug-resistant Acinetobacter baumannii (MDRAB), Escherichia coli (ATCC25922), Klebsiella pneumoniae (ATCC700603), and Acinetobacter baumannii (ATCC19606).

4. Use of the antimicrobial peptide according to claim 1 in the preparation of drugs for preventing and treating bacterial diseases of silkworms.

5. The use of the antimicrobial peptide according to claim 4 in the preparation of a method for preventing and treating bacterial diseases of silkworms, characterized in that: The antimicrobial peptide is used in the preparation of in vivo and in vitro drugs for resisting Enterococcus monnieri, a pathogenic bacterium of silkworm.

6. A method for preparing the antimicrobial peptide according to claim 1, characterized in that: The peptide was synthesized and prepared by solid phase synthesis. MBHA resin was selected as a solid phase carrier. The resin was first swelled and then the protecting group was removed. The first amino acid was connected to the resin. Then the remaining amino acids were connected to the resin in sequence. After each connection, the Fmoc protecting group on the amino acid was removed. After the connection of all peptide chains was completed, the antimicrobial peptide was cut from the resin and separated and purified by high performance liquid chromatography.

7. The method for preparing the antimicrobial peptide according to claim 6, characterized in that: When connecting amino acids, the activator O-benzotriazole-tetramethyluronium hexafluorophosphate is used to promote the coupling reaction of amino and carboxyl groups.

8. The method for preparing the antimicrobial peptide according to claim 7, characterized in that: The Fmoc protecting group on the amino acid was removed using an N,N-dimethylformamide solution containing 20% ​​piperidine by volume.

9. The method for preparing the antimicrobial peptide according to claim 8, characterized in that: The antimicrobial peptide was cut from the resin using a mixed solution of trifluoroacetic acid, water and triisopropylsilane in a volume ratio of 95%:2.5%:2.5% as a cutting liquid.

Citation Information

Cited By

  • Application of antibacterial peptide

    CN121796549A

  • Antibacterial peptide based on D-type amino acid and application thereof

    CN121800871A

  • D-amino acid-based antibacterial peptide and application thereof

    CN121800871B